title: Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease.
authors.affiliation: Department of Cardiology, Hospital & University of Fribourg, Fribourg, Switzerland.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cook
authors.forename: Holger
authors.initials: H
authors.lastname: Nef
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.forename: Andreas
authors.initials: A
authors.lastname: Baumbach
mesh_terms: D020341:Absorbable Implants; D000970:Antineoplastic Agents / Q000008:administration & dosage; D019917:Blood Vessel Prosthesis Implantation; D003324:Coronary Artery Disease / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D054457:Tissue Scaffolds
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus